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Residual neuromuscular blockade, defined by a train-of-four ratio less than 0.9, is associated with impaired 
function of respiratory and pharyngeal muscles with an 
increased risk of hypoventilation, hypoxia, upper-airway 
obstruction, and pulmonary aspiration.1–5 Importantly, 
Eikermann et al.2 demonstrated that even when the train-
of-four ratio fully recovered to unity, respiratory function 
tests (e.g., forced vital capacity) may still be depressed in 
some patients. There is now robust evidence that nonde-
polarizing neuromuscular blocking agents additionally 
influence ventilatory control by acting within the periph-
eral chemoreflex loop at the carotid bodies.6–11 The carotid 
bodies are located at the bifurcation of the common 
carotid artery and are important sensors involved in main-
taining respiratory homeostasis.12 For example, in case of 
hypoxia, carotid body activation results in hyperventilation 
aimed at increasing pulmonary oxygen uptake. The carotid 
body response to hypoxia (the acute hypoxic ventilatory 
response) is a life-saving reflex that is impaired by various 
drugs used in the perioperative phase, including opioids and 
anesthetics.13,14 In two pivotal studies in the early 1990s, 
Eriksson et al.6,7 showed in humans that the nondepolariz-
ing neuromuscular blocking agent vecuronium at a train-
of-four ratio of 0.7 blunts the acute hypoxic ventilatory 
response by 15 to 60%. Because the acute hypoxic venti-
latory response was significantly more depressed than the 
hyperoxic ventilatory response to carbon dioxide (which is a 
central chemoreflex response), an effect of vecuronium on 
the peripheral chemoreflex loop seems most likely. Animal 
studies give further proof for a selective effect of neuromus-
cular blocking agents at neuronal nicotinic acetylcholine 
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Background: The ventilatory response to hypoxia is a life-saving chemo-
reflex originating at the carotid bodies that is impaired by nondepolarizing 
neuromuscular blocking agents. This study evaluated the effect of three strat-
egies for reversal of a partial neuromuscular block on ventilatory control in 
34 healthy male volunteers on the chemoreflex. The hypothesis was that the 
hypoxic ventilatory response is fully restored following the return to a train-
of-four ratio of 1.
Methods: In this single-center, experimental, randomized, controlled trial, 
ventilatory responses to 5-min hypoxia (oxygen saturation, 80 ± 2%) and ven-
tilation at hyperoxic isohypercapnia (end-tidal carbon dioxide concentration, 
55 mmHg) were obtained at baseline, during rocuronium-induced partial neu-
romuscular block (train-of-four ratio of 0.7 measured at the adductor pollicis 
muscle by electromyography), and following reversal until the train-of-four 
ratio reached unity with placebo (n = 12), 1 mg neostigmine/0.5 mg atropine 
(n = 11), or 2 mg/kg sugammadex (n = 11).
results: This study confirmed that low-dose rocuronium reduced the ven-
tilatory response to hypoxia from 0.55 ± 0.22 (baseline) to 0.31 ± 0.21 l · 
min−1 · %−1 (train-of-four ratio, 0.7; P < 0.001). Following full reversal as 
measured at the thumb, there was persistent residual blunting of the hypoxic 
ventilatory response (0.45 ± 0.16 l · min−1 · %−1; train-of-four ratio, 1.0; 
P < 0.001). Treatment effect was not significant (analysis of covariance, 
P = 0.299) with chemoreflex impairment in 5 (45%) subjects following sugam-
madex reversal, in 7 subjects (64%) following neostigmine reversal, and in 10 
subjects (83%) after spontaneous reversal to a train-of-four ratio of 1.
conclusions: Despite full reversal of partial neuromuscular block at the 
thumb, impairment of the peripheral chemoreflex may persist at train-of-four 
ratios greater than 0.9 following reversal with neostigmine and sugammadex 
or spontaneous recovery of the neuromuscular block.
(ANESTHESIOLOGY 2019; XXX:00–00)
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What We Already Know about This Topic
• The ventilatory response to hypoxia is a critical reflex that is impaired 
by neuromuscular blocking drugs. However, the degree to which this 
reflex is restored after reversal of blockade is unknown.
What This Article Tells Us That Is New
• Despite full reversal of neuromuscular blockade at the thumb using 
different drug classes, this hypoxic chemoreflex is not fully restored.
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receptors located postsynaptically on the afferent nerve that 
connects the oxygen sensing or glomus cells of the carotid 
bodies to the brainstem.9–11
Eriksson8 showed later similar results for atracurium and 
pancuronium and additionally demonstrated that sponta-
neous return of the train-of-four ratio to values greater 
than 0.9 resulted in the recovery of acute hypoxic ventila-
tory response to values not different from control, although 
some subjects showed persistent depression of the hypoxic 
response. The picture that emerges from human and animal 
data from the Eriksson research group is that nondepolar-
izing neuromuscular blocking agents, irrespective of their 
chemical structure or receptor affinity, significantly impair 
the peripheral chemoreflex at the carotid bodies at train-of-
four ratios less than 0.9. So far, no other laboratories repli-
cated Eriksson’s human studies. The aim of our study was 
twofold. We replicated the concept of the human studies 
originally performed by Eriksson et al.6–8 with rocuronium 
to confirm their results for a nondepolarizing neuromus-
cular blocking agent not yet studied. Additionally, we mea-
sured the acute hypoxic ventilatory response, the hyperoxic 
hypercapnic ventilatory response after recovery of the par-
tial neuromuscular block (as measured at the thumb), fol-
lowing reversal with neostigmine and sugammadex versus 
placebo. We hypothesized that the carotid body–mediated 
hypoxic ventilatory response is fully restored following the 




This single-center, double-blind, parallel, randomized 
controlled trial was performed at the Anesthesia and Pain 
Research Unit of the Department of Anesthesiology 
at Leiden University Medical Center  (Leiden, The 
Netherlands) from May 2017 to September 2018. The pro-
tocol was approved by the local institutional review board 
(Commissie Medische Ethiek, Leiden, The Netherlands) 
and the Central Committee on Research Involving Human 
Subjects in The Hague, The Netherlands. The study was 
registered at the trial register of the Dutch Cochrane 
Center  (Amsterdam, The Netherlands) under identifier 
6427 (May 4, 2017). Before enrollment and after being 
informed about the study, all participants gave written 
informed consent. All study procedures were conducted 
according to good clinical practice guidelines and adhered 
to the tenets of the Declaration of Helsinki.
Subjects
Healthy male volunteers aged 18 yr or older and a body mass 
index less than 30 kg/m2 were eligible to participate in the 
study. Exclusion criteria were (1) known or suspected neu-
romuscular disorders impairing neuromuscular function; (2) 
suspected allergies to muscle relaxants, anesthetics, or nar-
cotics; (3) a history (self or family) of malignant hyperther-
mia or any other muscle disease; (4) any medical, neurologic, 
or psychiatric illness (including a history of anxiety); (5) 
inability to give informed consent; and (6) signs (or history) 
of a possible difficult intubation. Subjects were asked not to 
eat or drink for at least 8 h before dosing with rocuronium. 
The subjects were not allowed to participate more than 
once in the study. The subjects were recruited and enrolled 
in the study by the study team.
Study Design
This study had a randomized, double-blind, placebo-con-
trolled parallel design. Upon arrival in the research unit, all 
subjects received an intravenous line for administration of 
study drugs. Participants were randomized to receive pla-
cebo (2 ml of normal saline), 1 mg of intravenous neostig-
mine (combined with 0.5 mg of atropine), or 2 mg/kg 
sugammadex, following a continuous rocuronium infusion 
for 90 to 120 min aimed at a train-of-four ratio of 0.7. 
Before and during the rocuronium infusion, acute hypoxic 
and hyperoxic hypercapnic tests were performed. After 
the rocuronium infusion was stopped and a reversal agent 
was administrated, another set of ventilatory tests was per-
formed. Throughout the study the subjects were monitored 
by electrocardiogram and oxygen saturation via a finger 
probe.
Initially, we had set out to obtain respiratory responses 
at two levels of neuromuscular blockade with train-of-four 
ratios 0.6 and 0.8. Especially at the deeper level of relax-
ation, we observed frequent upper-airway obstructions that, 
although short-lived and not hazardous, interfered with the 
control of end-tidal carbon dioxide and oxygen concen-
trations. We therefore decided to change the protocol to 
studying just one level of blockade in between the orig-
inal targets. Additionally, we originally intended to study 
repetitive hypoxic exposures following reversal to measure 
the acute hypoxic ventilatory response at increasing train-
of-four ratio values (from 0.7 to 1). However, we observed 
that the train-of-four ratio returned rather rapidly toward 1 
and therefore decided to obtain one measurement of acute 
hypoxic ventilatory response at the time point at which the 
train-of-four ratio was first equal to 1. All changes were 
made after consultation with the data safety committee, 
were approved by the institutional review board, and docu-
mented in the trial registry.
Ventilatory Measurements
During ventilatory measurements, subjects were in the 
semirecumbent position. The ventilatory responses to 
hypoxia and hypercapnia were obtained using the dynamic 
end-tidal forcing technique. The technique is described 
in detail elsewhere.15,16 In brief, subjects breathed through 
a facemask that was attached to a pneumotachograph and 
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pressure transducer system (catalog no. 4813; Hans Rudolph 
Inc., USA) and to a set of mass flow controllers (Bronkhorst 
High Tech, The Netherlands) for the delivery of oxygen, car-
bon dioxide, and nitrogen. The mass flow controllers were 
controlled by a computer running software (RESREG/
ACQ, Leiden University Medical Center, The Netherlands) 
that steers end-tidal gas concentrations (by varying the 
inspired concentration) and collects respiratory variables. 
The inspired and expired oxygen and carbon dioxide partial 
pressures were measured at the mouth using a capnograph 
(Datex Capnomac, Finland); heart rate and arterial oxy-
gen saturation were measured by pulse oximetry (Masimo 
Corporation, USA). The following variables were collected 
on a breath-to-breath basis and averaged over 1 min for fur-
ther analysis: minute ventilation (V
E
), end-tidal carbon diox-
ide concentration (ETco
2
), end-tidal oxygen concentration 
(ETo
2
), and arterial oxygen saturation (Spo
2
).
To obtain the isocapnic hypoxic ventilatory response, we 
performed steps into hypoxia by lowering the ETo
2
 to 52 
mmHg such that the Spo
2
 dropped to 80 ± 2%. The hypoxic 
test took about 7 to 9 min, i.e., 2 to 4 min of normoxia (ETo
2
 
100 mmHg) followed by 5 min of hypoxia. Throughout the 
experiment the ETco
2
 was kept constant at 1 to 2 mmHg 
above resting values. To obtain the hyperoxic hypercapnic 
ventilatory response, we applied three 5- to 7-min steps in 
ETco
2
 with step sizes of 7.5, 10, and 15 mmHg. To suppress 
the contribution of the carotid bodies to the hypercapnic 
response, all hypercapnic tests were performed in hyper-
oxia (inspired oxygen fraction, 0.5).15 The hypoxic venti-





 data using the last 2 min of normoxia and hypoxia. 
The hypercapnic ventilatory sensitivity was calculated by 




 data using the last 2 min 
of each hypercapnic step. This analysis provided the slope 
of the hypercapnic ventilatory response (S) and the extrap-
olated x-axis intercept (apneic threshold, B). Next, we cal-
culated ventilation at an extrapolated ETco
2
 of 55 mmHg 
(V
E
55) using the following equation V
E
55 = S × (55 − B). 
Ventilation at an extrapolated ETco
2
 of 55 mmHg takes 
the slope and the position of the hypercapnic ventilatory 
response into account and hence gives a reliable reflection 
of the effect of the intervention on hypercapnic ventila-
tory control (see fig. 2 of van der Scrier et al.).17 To ensure 
that responses were unaffected by previous responses, we 
allowed rest periods between measurements. Additionally, 
minute ventilation was assessed in real time on-screen, and 
only when ventilation had returned to baseline levels was 
the next ventilatory measurement initiated.
Experiments were performed at baseline (before any 
drug administration), at a stable neuromuscular block 
with train-of-four ratio equals 0.7, and after recovery to a 
train- of-four ratio equals 1. The sequence of hypoxic and 
hypercapnic tests was randomized at baseline and during 
rocuronium infusion; however, following return of the 
train-of-four ratio to 1 after reversal, first one hypoxic test 
was obtained followed by the hypercapnic test.
Drug Administration
All drugs were given intravenously. For rocuronium (Esmeron, 
MSD BV, The Netherlands), the dosing was dependent on the 
measured train-of-four ratio. In all subjects the initial bolus 
dose was 5 mg, after which a rocuronium continuous infu-
sion was started at 0.42 mg/min. Additional bolus doses of 1 
to 5 mg were given, and/or the infusion rate was modified 
when the train-of-four ratio remained above the target. In 
case of an overshoot with train-of-four ratios of less than 0.7, 
the infusion was lowered until the target was reached. At the 
desired train-of-four ratio target, we waited 10 to 15 min, and 
when the train-of-four ratio remained stable, the first respi-
ratory test was performed. Otherwise the infusion rate was 
further adapted until the target was reached. On average, 55 
± 15 mg rocuronium was given throughout the experiment. 
The rocuronium dosing was based on simulations using the 
pharmacokinetic data set of Kleijn et al.18 The reversal agents 
1 mg of neostigmine (Hameln Pharmaceuticals Ltd., United 
Kingdom), 2 mg/kg sugammadex (Bridion, MSD BV), and 
2 ml of placebo (NaCl 0.9%) were given as a bolus infusion 
when the rocuronium infusion was stopped. In case of an 
upper-airway obstruction or severe respiratory depression 
(with Spo
2
 less than 70%) due to a more intense neuro-
muscular block than intended, the subject received 2 mg/kg 
sugammadex, and the experiment was ended.
Measurement of the Neuromuscular Block
Neuromuscular block was measured by electromyography at 
the adductor pollicis muscle, using the CARESCAPE B450 
monitor combined with the  electromyography–neuromus-
cular transmission module (both General Electric, Finland). 
After degreasing the skin with alcohol, the electrodes were 
placed at the wrist according to the guidelines of the man-
ufacturer (in the arm opposite to the arm with the intrave-
nous line). Before administration of rocuronium, a series of 
measurements were obtained at a stimulus strength of 30 mA. 
Stable recordings were verified and defined as a difference in 
train-of-four ratio of less than 5% in three consecutive mea-
surements. All subsequent measurements were obtained at 
1-min intervals. Skin temperature was maintained through-
out the study by keeping a constant room temperature.
Randomization and Allocation
Randomization (placebo:neostigmine:sugammadex equals 
1:1:1) was performed by an independent third party 
(research nurse not involved in the study) using a computer- 
generated randomization list. On the day of the experiment, 
each subject was allocated to treatment, and all study medi-
cation was delivered to the laboratory by the same nurse in 
unmarked sequentially numbered syringes of equal size and 
volume. In case of neostigmine administration, the syringe 
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additionally contained 0.5 mg of atropine. The study was 
independently monitored, ensuring all Good Clinical 
Practices requirements were met.
Statistical Analysis
No formal sample size analysis was performed because we 
based our samples size on the previous studies of Eriksson 
et al.6–8 We defined the acute hypoxic response (AHR), slope of 
the hypercapnic ventilatory response (HCVR), and ventilation 
at an extrapolated ETco
2
 of 55 mmHg (V
E
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, and after recovery of the neuromuscular 









We calculated the ratio of acute hypoxic response and ven-
tilation at an extrapolated ETco
2
 of 55 mmHg relative to 























































 as carotid body index (i.e., markers of 





exceeded baseline ventilation at an extrapolated ETco
2
 of 55 




 values of more than 
100%. We consider this excitatory phenomenon a procedural 
effect because the hypercapnic test after reversal was always 
performed after the hypoxic test. Because this may have under-
estimated the effect of reversal treatment on F
3











 to 100% 
in case values of more than 100% were observed.
All data were checked for normality by evaluation of their 
empirical distribution (i.e., by histogram). The effects of treat-
ment on acute hypoxic response, slope of the hypercapnic 
ventilatory response, and ventilation at an extrapolated ETco
2
 
of 55 mmHg were analyzed by one-way ANOVA (factor: 
treatment) with post hoc Holm–Sidak multiple comparison 
test to compare treatment effect (either measurement 2 or 
3) to control (baseline) data. The hypoxic and hypercapnic 
ratios F were compared to 1 using two-tailed paired t tests. 
These analyses were performed (using a two-tailed approach) 
on the complete data set and on the three distinct reversal 
treatments, allowing within-group comparison. To test our 
hypothesis that at a train-of-four ratio of 1 the responses fully 
returned to baseline levels irrespective of the reversal strategy, 









, with the baseline as covariate and treatment (placebo, 
neostigmine, sugammadex) as fixed effect. To compare the F
3
 
ratios among treatments, a one-way ANOVA was performed. 
If a significant main effect was observed, protected post hoc 
tests were performed. The statistical analysis was performed 
using GraphPad Prism version 7 for Mac OS X (GraphPad 
Software, USA) and SPSS Statistics for Windows  (IBM, 
USA), version 23.0. P values of less than 0.05 were consid-
ered significant. All values are means ± SD unless otherwise 
stated; the data in the figures are means ± 95% CI.
results
In the amended protocol 40 subjects were randomized 
(fig. 1). All subjects completed the protocol without seri-
ous adverse events. Four subjects developed upper-airway 
obstruction: three during the administration of rocuro-
nium and one during recovery following placebo reversal. 
All four were treated with sugammadex, after which they 
fully recovered; they were taken out of the study, and each 
was replaced by another subject. The characteristics of the 
Fig. 1. Consort flow diagram.
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36 subjects that completed the study are given in table 1. 
Data from two subjects (one in the neostigmine group and 
the other in the sugammadex group) were unreliable due 
to lack of calibration. Consequently, the data from 34 sub-
jects were analyzed. Apart from upper-airway obstruction, 
adverse effects included diplopia (80%), difficulty swallow-
ing (40%), and ptosis (10%). After reversal, all subjects recov-
ered fully. None of the subjects reported the occurrence of 
distress or anxiety during relaxation.
Influence of Low-dose Rocuronium and Reversal on 
Ventilatory Control
Upon the administration of rocuronium, the train-of-four 
ratio decreased slowly and reached a steady state of 0.68 ± 
0.01 (fig. 2) within 45 min, after which the respiratory tests 
were performed. During the hypoxic tests, the ETco
2
 aver-
aged to 41.1 ± 2.5 mmHg in control studies, 41.5 ± 2.6 
mmHg in rocuronium studies, and 41.4 ± 2.6 mmHg in 
reversal studies. Hypoxic ventilator sensitivities during con-
trol, during relaxation, and after reversal were 0.55 ± 0.22 
(AHR
1
), 0.31 ± 0.20 (AHR
2
), and 0.45 ± 0.16 (AHR
3
) l · 









P < 0.001; table  2), respectively. AHR
2





 was depressed by 11% (tables  2 and 3). 
Consequently, the effect of low-dose rocuronium on AHR
2
 
may be attributed largely to carotid body impairment with 
carotid body index F
2
 = 0.67 ± 0.32 (P < 0.001; table 4). 
Following reversal, AHR
3










 exceeded baseline values in 29 subjects. After 
adjustment for this excitatory effect, the corrected carotid 
body index F
3
 value averaged 0.89 ± 0.34 (P = 0.076).
Neostigmine, Sugammadex, and Placebo Reversal
Subject characteristics were similar among the three treat-
ment groups (table 1). The train-of-four ratio recovery pro-
files for the three treatments are given in figure  2B. The 
times from reversal until the start of the hypoxic studies 
were 2.5 ± 0.7 (range 1 to 3) min, 8.2 ± 3.2 (4 to 16) min, 
and 15.1 ± 4.6 (12 to 25) min, for reversal with sugam-
madex, neostigmine, and placebo, respectively (arrows in 
fig.  3B). Although the magnitude of the control hypoxic 
responses among the three treatment groups varied (AHR
1
 
in table 2), these variations were not significantly different 
(P = 0.175), and partial relaxation by low-dose rocuronium 
resulted in a similar reduction by 38 to 46% (AHR
2
) in the 
three treatment groups.
table 1. Subject Characteristics
 reversal Group
 all Subjects Placebo neostigmine Sugammadex
Age, median [range], yr 22 [18–29] 20 [19–29] 23 [18–29] 23 [19–25]
Weight, mean ± SD, kg 80 ± 10 79 ± 9 77 ± 10 86 ± 10
Height, mean ± SD, cm 185 ± 8 186 ± 10 187 ± 9 187 ± 8
Body mass index, mean ± SD, kg ∙ m−2 23.1 ± 2.1 22.6 ± 1.5 22.2 ± 2.1 24.7 ± 2.2
Fig. 2. (A) Average train-of-four (TOF) ratio values during infusion of low-dose rocuronium (n = 36). Hypoxic and hypercapnic experiments 
were performed from t equals 45 to t equals 120 min (average TOF ratio, 68 ± 1%), after which reversal agents were given. (B) Effect of reversal 
with placebo (green symbols), neostigmine (blue symbols), and sugammadex (red symbols) on TOF ratios. The arrows indicate the mean times 
at which data collection of the hypoxic ventilatory response was started (hypoxic responses took 7 to 9 min). The values are means ± 95% CI.
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When considering the complete study population, 
reversal to a train-of-four ratio equals 1 led to an AHR
3
 
of 0.45 ± 0.16 l · min−1 · %−1 (P < 0.001 vs. AHR
1
) or 
a residual 18% depression compared to baseline. Within-
group comparisons are given in table  2. The treatment 
effect (between-group comparison) did not reach the 
level of significance (analysis of covariance main effect 
P = 0.299), indicating that the three reversal strategies 
had a similar effect on the acute hypoxic ventilatory 
response. Relative to control levels, all treatments pro-
duced a similar increase in the hypercapnic ventilatory 
response (analysis of covariance main effect P = 0.938) 
and ventilation at an extrapolated ETco
2
 of 55 mmHg 
(analysis of covariance main effect P = 0.679; tables  2 





 values are given in table 4 and fig-
ure  3. The uncorrected and corrected F
3
 values in the 
complete population were 0.78 ± 0.35 (P = 0.001) and 
0.89 ± 0.34 (P = 0.076), respectively. Neither for the 
corrected nor for the uncorrected F ratios a significant 
treatment effect was observed (F
3
 uncorrected, ANOVA 
main effect P = 0.231; F
3
 uncorrected ANOVA main 
effect P = 0.232). Corrected F
3
 values less than 0.95 were 
observed in 10 subjects in the placebo group, 7 in the 
neostigmine group, and 5 in the sugammadex group.
table 2. Acute Hypoxic Response and Slope of the Hypercapnic Ventilatory Responses Obtained at Baseline, during Infusion of Low-
dose Rocuronium and after Reversal with Placebo, Neostigmine, or Sugammadex
treatment
aHr1,  
l · min−1 · %−1
aHr2,  
l · min−1 · %−1
aHr3,  
l · min−1 · %−1
Hcvr1,  
l · min−1 · mmHg−1
Hcvr2,  
l · min−1 · mmHg−1
Hcvr3,  
l · min−1 · %−1
All treatments 0.55 ± 0.22 0.31 ± 0.20 0.45 ± 0.16 2.02 ± 0.66 1.51 ± 0.48 2.20 ± 0.96
 Mean difference 
(95% CI)
 −0.23 (−0.30 to −0.16), 
P < 0.001 vs. AHR1
−0.10 (−0.15 to −0.05), 
P < 0.001 vs. AHR1
 −0.50 (−0.63 to −0.37), 
P < 0.001 vs. HCVR1
0.19 (−0.02 to 0.40),  
P = 0.094 vs. HCVR1
Placebo 0.66 ± 0.21 0.34 ± 0.22 0.49 ± 0.13 2.34 ± 0.69 1.68 ± 0.44 2.33 ± 0.88
 Mean difference 
(95% CI)
 −0.33 (−0.49 to −0.17), 
P = 0.003 vs. AHR1
−0.18 (−0.26 to −0.10), 
P = 0.002 vs. AHR1
 −0.66 (−0.94 to −0.38), 
P = 0.001 vs. HCVR1
−0.01 (−0.38 to 0.36), 
P = 0.965 vs. HCVR1
Neostigmine 0.43 ± 0.23 0.29 ± 0.20 0.36 ± 0.20 1.81 ± 0.71 1.24 ± 0.47 2.05 ± 1.11
 Mean difference 
(95% CI)
 −0.15 (−0.20 to −0.10), 
P < 0.001 vs. AHR1
−0.07 (−0.18 to 0.02),  
P = 0.074 vs. AHR1
 −0.56 (−0.77 to −0.35), 
P = 0.001 vs. HCVR1
0.24 (−0.03 to 0.51),  
P = 0.106 vs. HCVR1
Sugammadex 0.54 ± 0.16 0.31 ± 0.17 0.48 ± 0.13 1.88 ± 0.48 1.60 ± 0.47 2.24 ± 0.95
 Mean difference 
(95% CI)
 −0.23 (−0.29 to −0.17), 
P < 0.001 vs. AHR1
−0.05 (−0.13 to 0.03),  
P = 0.241 vs. AHR1
 −0.27 (−0.47 to −0.07), 
P = 0.004 vs. HCVR1
0.37 (−0.10 to 0.84),  
P = 0.149 vs. HCVR1
Main treatment effect 
(ANCOVA)
  P = 0.299   P = 0.938
The values are mean ± SD. AHR is the acute isocapnic hypoxic response; HCVR is the hyperoxic hypercapnic ventilatory response slope. AHR1 and HCVR1 are response obtained at 
baseline, AHR2 and HCVR2 are response obtained during infusion of rocuronium, AHR3 and HCVR3 are responses obtained following reversal. All within group statistical comparisons 
are relative to the baseline value (AHR1 or HCVR1). To assess the treatment effect on AHR3 and HCVR3, an analysis of covariance (ANCOVA) with baseline values (AHR1, HCVR1) as 
covariate and treatment as fixed effect was performed.
table 3. Ventilation at Extrapolated End-tidal Carbon Dioxide Concentration of 55 mmHg Measured at Baseline, during Low-dose 
Rocuronium Infusion and after Reversal with Placebo, Neostigmine, or Sugammadex
treatment ve551 ve552 ve553
All treatments, l/min 32 ± 9 28 ± 7 37 ± 11
 Mean difference (95% CI)  −3.9 (−5.5 to −2.3), P < 0.001 vs. VE551 5.0 (3.5 to 6.5), P < 0.01 vs. VE551
Placebo, l/min 35 ± 11 30 ± 8 39 ± 11
 Mean difference (95% CI)  −5.5 (−9.1 to −1.9), P = 0.020 vs. VE551 3.7 (−1.0 to 8.4), P = 0.159 vs. VE551
Neostigmine, l/min 29 ± 7 26 ± 7 34 ± 9
 Mean difference (95% CI)  −3.0 (−5.0 to −1.0), P = 0.026 vs. VE551 4.9 (2.6 to 7.2), P < 0.01 vs. VE551
Sugammadex, l/min 31 ± 8 27 ± 7 37 ± 14
 Mean difference (95% CI)  −3.2 (−5.2 to −1.2), P = 0.038 vs. VE551 6.6 (−0.2 to 13.4), P = 0.092 vs. VE551
Main treatment effect (ANCOVA)   P = 0.679
The values are mean ± SD. VE55 is ventilation at an extrapolated extrapolated end-tidal carbon dioxide concentration of 55 mmHg. VE551 is hypercapnia ventilation measured at 
baseline, VE552 is hypercapnia ventilation measured during infusion of rocuronium, VE553 is hypercapnic ventilation measured following reversal. To assess treatment effect on VE553, 
an analysis of covariance (ANCOVA) with the baseline value as covariate (VE551) and treatment as fixed effect was performed.
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table 4. Ratios of the Acute Hypoxic Response (AHR) and Ventilation at an Extrapolated End-tidal Carbon Dioxide Concentration 
of 55 mmHg (VE55) Relative to Baseline (%) Obtained during Infusion of Low-dose Rocuronium (AHR2R and VE552R) and after 
Reversal with Placebo, Neostigmine, or Sugammadex (AHR3R and VE553R) and Carotid Body Indices Obtained during Low-dose 
Rocuronium Infusion (F2) and after Reversal (F3)
treatment
Low-dose rocuronium (toF ratio = 0.7) reversal (toF ratio = 1)









All treatments 57 ± 26 89 ± 11 0.66 ± 0.32 86 ± 25 115 ± 23 98 ± 7 0.78 ± 0.35 0.89 ± 0.34
 Discrepancy (vs. 1) 
(95% CI)
  −0.34 (−0.45 to −0.23), 
P < 0.001
   −0.22 (−0.34 to −0.10), 
P = 0.001
−0.11 (−0.23 to 0.01), 
P = 0.076
Placebo 54 ± 33 85 ± 11 0.65 ± 0.43 76 ± 16 115 ± 24 97 ± 8 0.68 ± 0.16 0.79 ± 0.25
 Discrepancy (vs. 1) 
(95% CI)
  −0.34 (−0.62 to −0.06), 
P = 0.019
   −0.32 (−0.42 to −0.22), 
P < 0.001
−0.21 (−0.31 to 0.11), 
P < 0.001
Neostigmine 62 ± 25 90 ± 12 0.69 ± 0.28 87 ± 27 117 ± 14 100 ± 0 0.75 ± 0.25 0.87 ± 0.27
 Discrepancy (vs. 1) 
(95% CI)
  −0.31 (−0.50 to −0.12), 
P = 0.004
   −0.25 (−0.41 to −0.09), 
P = 0.008
−0.13 (−0.30 to 0.04), 
P = 0.128
Sugammadex 56 ± 16 90 ± 12 0.64 ± 0.23 95 ± 29 112 ± 30 96 ± 8 0.93 ± 0.53 1.03 ± 0.5
 Discrepancy (vs. 1) 
(95% CI)
  −0.36 (−0.52 to −0.20), 
P < 0.001
   −0.07 (−0.42 to 0.28),  
P = 0.661
0.03 (−0.30 to 0.36),  
P = 0.842
Main treatment effect 
(ANOVA)
      P = 0.231 P = 0.232
The values are means ± SD. To assess treatment effect on the F ratios, a one-way ANOVA was performed.
TOF, train of four.
Fig. 3. Influence of three reversal strategies on the acute hypoxic response and carotid body index F3. (A) AHR3R indicates the acute hypoxic 
ventilatory response after reversal as a percentage of the baseline response. (B) Uncorrected carotid body index F3, which is the ratios AHR3R/
VE553R or the ratio of the changes in acute hypoxic response and ventilation at an extrapolated end-tidal carbon dioxide concentration of 55 
mmHg (VE55), relative to baseline, after reversal and full recovery of neuromuscular function at the thumb. (C) Corrected carotid body index 
F3, with VE553R constrained to 100% in case of values exceeding 100%. The values are the means ± 95% CI. Between-treatment comparisons 
were done by analysis of covariance with baseline value as covariate. CB, carotid body.
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The main outcomes of our experimental study are summa-
rized as follows:
(1) Rocuronium-induced partial neuromuscular blockade 
(train-of-four ratio ≈ 0.7) blunts the isocapnic hypoxic 
response by 42%, whereas hypercapnic ventilation was 
reduced by just 11% (table  3). As estimated from the 
carotid body index (F
2
 = 0.67), the depression of the 
hypoxic response is primarily due to an effect on the 
peripheral chemoreflex loop. The additional depression 
of the hypoxic response is most probably related to mild 
respiratory muscle weakness.
(2) Reversal of the neuromuscular block to a train-of-four 
ratio of 1 did not result in a complete return of the acute 
hypoxic response to baseline values (AHR
3
 = 86 ± 25% of 
baseline, P = 0.002). We therefore reject the null hypoth-
esis that full reversal of the neuromuscular block at the 
thumb results in a complete return of the acute hypoxic 
ventilatory response. Interestingly, this residual effect was 
independent of reversal strategy with 62% of subjects that 
still had AHR
3
 values less than 95% of baseline (placebo n 
= 10, neostigmine n = 7, and sugammadex n = 5).
Partial Neuromuscular Blockade
In the first part of our study, we convincingly replicate the 
findings of Eriksson et al.6–8 and show that partial neuromus-
cular block reduces the acute hypoxic response primarily via 
an effect at the carotid bodies. As proposed by Eriksson et al.,7 
the separation between carotid body and muscle effects on 
ventilatory control was performed by calculating the carotid 
body index F
2






 or the ratio 
of relative changes in hypoxic response and ventilation at an 
extrapolated ETco
2
 of 55 mmHg. Because ventilation at an 
extrapolated ETco
2
 of 55 mmHg was obtained at hyperoxia, 
ventilation at an extrapolated ETco
2
 of 55 mmHg is mini-
mally influenced by carotid body activity. Hyperoxia silences 
the contribution of the carotid bodies to hypercapnic ven-
tilation, which is 10 to 20% under normoxic conditions 
versus 0 to 5% under hyperoxic conditions.15 Impairment 
of the hypoxic response via the respiratory muscles rather 
than carotid bodies would have resulted in carotid body 
index values not different from 1.7 The rocuronium F
2
 value 
of 0.66 (95% CI, 0.55 to 0.77) is smaller than the F value 
earlier observed for vecuronium (F = 0.84).7,8 This suggests 
a greater potency of rocuronium at impairing the carotid 
bodies compared with vecuronium.
Our data indicate a small non–carotid body–related 
effect on the hypoxic response during low-dose rocuronium 
infusion. Although this is most probably due to respiratory 





cannot exclude other causes. Theoretically, one such cause 
could be a decrease in arousal level from deafferentation 
related to reduced muscle spindle input to central sites. 
There is ample evidence that peripheral deafferentation 
from spinal or epidural anesthesia changes the brain sen-
sory and arousal states.19,20 A reduction in arousal level will 
decrease hypoxic response.14 Because we did not detect any 
obvious changes in arousal during partial muscle relaxation, 
we conclude that the non–carotid body–related effect of 
low-dose rocuronium on hypoxic response was related to 
mild respiratory muscle weakness. Although in line with 
the findings of Eikermann et al.2 on rocuronium, our data 
differ from those of Eriksson et al.,6–8 who observed no 
effect of partial neuromuscular block on the slope of the 
hypercapnic ventilatory response. These differences may be 
attributed to differences in protocol or differences in drug 
sensitivity with greater rocuronium sensitivity in relaxation 
of respiratory muscles compared with other relaxants.
Reversal of the Partial Neuromuscular Blockade
The between-group comparison indicated that despite full 
reversal of partial neuromuscular block as evidenced by 
the measurement of the train-of-four ratio of 1 and a fully 
restored ventilation at an extrapolated ETco
2
 of 55 mmHg, 
impairment of the peripheral chemoreflex persisted in the 
majority of subjects, irrespective of the reversal strategy. It is 
further of interest to discuss the within-group comparisons.
Placebo. Following placebo reversal and recovery of the 
train-of-four ratio to values more than 0.90 as measured at 
the thumb, the hypoxic response was just 76% of control, 
whereas ventilation at an extrapolated ETco
2
 of 55 mmHg 
was fully restored. The resultant reduced carotid body index 
indicates that despite the return of muscle function at the 
thumb, carotid body function remained suboptimal. A pos-
sible explanation is a difference in rocuronium affinity for 
muscle versus neuronal nicotinic acetylcholine receptors. In 
vitro experiments give evidence for the distinct pharma-
cologic properties of rocuronium at various human mus-
cle and neuronal nicotinic acetylcholine receptor subtypes 
expressed on Xenopus oocytes.21 However, functional affinity 
of nondepolarizing muscle relaxants was higher for muscle 
type receptors, with half-maximum inhibitory concen-
trations in the nanomolar concentration range for muscle 
nicotinic acetylcholine receptors versus micromolar range 
for neuronal nicotinic acetylcholine receptors. This seems 
to contradict our findings. Still, reversal of rocuronium-im-
paired carotid body function is a dynamic process that is 
influenced by several factors, such as acetylcholine receptors 
receptor kinetics at pre- and postsynaptic sites (including 
involvement of specific receptor subtypes), local blood flow, 
local acetylcholine and acetylcholinesterase concentrations, 
interaction with other (including muscarinic acetylcholine, 
dopamine, purinergic) receptors, receptor (de)sensitization, 
neuronal dynamics, etc. Currently, little is known about this 
complex process, and we postulate that reversal of the rocu-
ronium effect at carotid bodies is slower than at peripheral 
muscles. This might not be so for the other nondepolar-
izing neuromuscular blockers, because Eriksson8 showed 
full recovery of hypoxic responses and F values following 
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spontaneous return of the train-of-four ratio to values of 
more than 0.9 after partial muscle relaxation induced by 
vecuronium, atracurium, and pancuronium.8
Neostigmine. Seven subjects (64%) had corrected F
3
 values 
less than 0.95 following reversal. Consequently, we argue 
that although neostigmine was effective in restoring muscle 
function at the thumb, it did not concurrently restore the 
hypoxic response in all subjects. We cannot exclude a possi-
ble role for atropine in this suboptimal reversal. Animal data 
indicate that atropine, a muscarinic acetylcholine receptor 
antagonist, significantly attenuates the carotid body response 
to hypoxia.22,23 Because data derived from human carotid 
bodies detected expression of just neuronal nicotinic acetyl-
choline receptors,24 a possible inhibitory effect of atropine 
on the hypoxic response in our sample seems unlikely. What 
remains is the possibility that the neostigmine dose (13 µg · 
kg−1) was sufficient to reverse respiratory muscle impairment 
but insufficient for full reversal of carotid body function in 
some subjects. Dose-response studies are needed to deter-
mine the dose required to restore carotid body function in 
all individuals following rocuronium relaxation.
Sugammadex. Five subjects (45%) had corrects F
3
 values 
less than 0.95. Consequently, even with sugammadex rever-
sal and restoration of muscle function at the thumb, the 
hypoxic response may not be restored in all patients.
Our data indicate that reversal to a train-of-four ratio of 1 
does not fully reverse blunting of the acute hypoxic response in 
most subjects. Because our protocol was unable to determine 
the timing at which the response returned to baseline val-
ues (i.e., AHR
3
 > 0.95 × AHR
1
), further studies are urgently 
needed to establish the dynamics of the return of the hypoxic 
response toward baseline following reversal strategies (neostig-
mine/atropine, sugammadex) or spontaneous recovery.
Trial Limitations
Although we randomized the hypoxic and hypercapnic tests 
during relaxation, we refrained from randomization fol-
lowing reversal. Although this was done to ensure that the 
hypoxic tests were performed at similar stages of reversal, 
this may have affected the hypercapnic test results. Indeed, 
ventilation at an extrapolated ETco
2
 of 55 mmHg values 
following reversal were on average 15% larger than control 
values. This observation made us decide to correct for this 





to 100% to prevent overestimation of the effect of the three 
reversal agents. Uncorrected and corrected F
3
 values differed 
by about 10%. However, because 22 of 34 subjects had a 
corrected F
3
 value of less than 0.95, we do not believe that 
this correction affected the clinical interpretation of the data.
Our method of measuring muscle relaxation may have 
been suboptimal. Although mechanomyography is con-
sidered the gold standard in neuromuscular monitor-
ing, electromyography is generally regarded a good and 
accurate alternative to mechanomyography25 and lacks 
the staircase effect that troubles acceleromyography or 
mechanomyography.26 However, measurements may have 
been influenced by the fact that our subjects were awake, 
which may have caused occasional (unnoticed) thumb 
movements disturbing the measurements with possibly some 
overestimation of the train-of-four ratio. In addition, supra-
maximal stimulation was not used to avoid a possible con-
founding effect of discomfort on respiratory measurements. 
Finally, train-of-four ratios were not corrected for baseline 
train-of-four ratio, which may have caused overestimation of 
the recovery of the neuromuscular block at the time of mea-
surement. However, this effect was relatively small (1 to 2%).
In conclusion, we successfully replicated the original 
study by Eriksson et al.6 showing an inhibitory effect of 
rocuronium at the carotid bodies. Our reversal data point 
toward persistence of carotid body impairment despite 
recovery of the train-of-four ratio to values of more than 
0.9 at the thumb. These are important and clinically rele-
vant observations. However, given the complexity of this 
experimental study, we highlight the need for further inves-
tigations. We encourage others to replicate our study and 
address the effect of spontaneous return of neuromuscular 
function following rocuronium relaxation on carotid body 
function. Finally, we would like to stress that in clinical 
practice, residual anesthetic and muscle relaxant levels syn-
ergistically affect breathing postoperatively. Further research 
should investigate such interactions with special emphasis 
on mechanisms and sites of action.
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